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A novel method for simultaneous determination of kolliphor HS15 and miglyol 812 in microemulsion
formulation was developed using ultra-high performance liquid chromatography coupled with a nano
quantitation analytical detector (UHPLC–NQAD). All components in kolliphor HS15 and miglyol 812 were
well separated on an Acquity BEH C18 column. Mobile phase A was 0.1% triﬂuoroacetic acid (TFA) in water
and mobile phase B was acetonitrile. A gradient elution sequence was programed initially with 60%
organic solvent, slowly increased to 100% within 8 min. The ﬂow rate was 0.7 mL/min. Good linearity
(r40.95) was obtained in the range of 27.6–1381.1 μg/mL for polyoxyl 15 hydroxystearate in kolliphor
HS15, 0.8–202.0 μg/mL for caprylic acid triglyceride and 2.7–221.9 μg/mL for capric acid triglyceride in
miglyol 812. The relative standard deviations (RSD) ranged from 0.6% to 1.7% for intra-day precision and
from 0.4% to 2.7% for inter-day precision. The overall recoveries (accuracy) were 99.7%–101.4% for
polyoxyl 15 hydroxystearate in kolliphor HS15, 96.7%–99.6% for caprylic acid triglyceride, and 94.1%–
103.3% for capric acid triglyceride in miglyol 812. Quantiﬁcation limits (QL) were determined as 27.6 μg/
mL for polyoxyl 15 hydroxystearate in kolliphor HS15, 0.8 μg/mL for caprylic acid triglyceride, and 2.7 μg/
mL for capric acid triglyceride in miglyol 812. No interferences were observed in the retention time
ranges of kolliphor HS15 and miglyol 812. The method was validated in terms of speciﬁcity, linearity,
precision, accuracy, QL, and robustness. The proposed method has been applied to microemulsion for-
mulation analyses with good recoveries (82.2%–103.4%).
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Kolliphor HS15 (also known as solutol HS15) is a potent non-
ionic solubilizer and emulsifying agent. It is particularly suitable
for microemulsion formulation [1]. Kolliphor HS15 mainly con-
tains polyoxyl 15 hydroxystearate obtained from the reaction of
about 15 mol of ethylene oxide with 1 mol of 12-hydroxystearic
acid [2]. Polyoxyl 15 hydroxystearate consists of about 70% of
polyglycol mono- and di-esters (lipophilic) and about 30% of free
polyethylene glycol (PEG, hydrophilic). Miglyol 812 is a mixture
of medium-chain fatty acid triglycerides obtained from the
esteriﬁcation of the fatty acids C8 and C10 with glycerin. Commercial
miglyol 812 contains four fatty acid triglycerides, i.e., C8-content
triglyceride, two mixed fatty acid triglycerides (by-product A and
by-product B) and low C10-content triglyceride [3].
Decades ago, many researchers found that kolliphor HS15 andon and hosting by Elsevier B.V. All
University.
ang).miglyol 812 not only improved the drug solubility and adsorption,
but also were associated with product stability and functionality
[4]. For example, Ryoo et al. [5] found when 1% (m/m) of propofol
was solubilized with 8% (m/m) of kolliphor HS15, the droplet size
and the amount of propofol in the microemulsion formulation
remained unchanged at 40 °C for eight weeks. During the study of
human epidermoid carcinoma cell line, Coon et al. [6] reported
that kolliphor HS15 could be used as a potential therapeutic agent
because of its effectiveness for reversing multidrug resistance in
vitro and low toxicity in vivo. Sellers et al. [7] investigated the ef-
fects of miglyol 812 on rats and found that miglyol 812 produced
reversible gastrointestinal effects and decreased body weight
gains after oral gavage for four weeks. Zhao et al. [8] described that
the treatment with caprylic triglyceride effectively attenuated
progression of weakness and protected spinal cord motor neuron
loss in amyotrophic lateral sclerosis (ALS) disease. Palin et al. [9]
found that miglyol 812 would increase the oral absorption of ce-
foxitin in rats when the drug was formulated in the oil phase,
possibly due to the transient effect of the fatty acid membrane
ﬂuidity. Janet et al. [10] reported that the batch variations of so-
lutol HS15 would impact the drug product performance; therefore,rights reserved. This is an open access article under the CC BY-NC-ND license
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assisted laser desorption/ionization (MALDI) and ion mobility to
control drug product quality.
For quality control purposes, the quantitative estimation of
kolliphor HS15 and miglyol 812 in microemulsion product is
paramount. To our knowledge, no analytical methods have been
reported for simultaneous determination of kolliphor HS15 and
miglyol 812 and very few methods have been published for in-
dividual analysis of kolliphor HS15 or miglyol 812. The Unites
States Pharmacopeia–National Formulary (USP37–NF32) [11] and
European Pharmacopoeia (EP-7.0) [12] describe a similar liquid
chromatographic (LC) method using a refractive index (RI) de-
tector for identifying and quantifying free PEG components from
kolliphor HS15. USP and EP methods both recommend the use of a
mobile phase of methanol and water (8:2, v/v) at a ﬂow rate of
1.1 mL/min. An analytical column along with two pre-columns is
used. The acceptance criteria for free PEG in kolliphor HS15 is set
as 27.0%–39.0%. These two compendial methods are dedicated
only for analysis of about 30% of hydrophilic (unesteriﬁed) portion
and are not suitable for analyzing polyglycol mono- and di-esters
(lipophilic, esteriﬁed) portion.
Coon et al. [6] described a gel permeation chromatography
(GPC) method for kolliphor HS15 under isocratic conditions and at
a constant ﬂow rate of 1.0 mL/min. Efﬂuent fractions were
monitored for absorbance at 254 nm. The buffer used was phos-
phate-buffered saline, pH 7.4. Gel chromatogram of kolliphor HS15
revealed one major peak at the retention time of about 7 min
(approximately 70% of total) and a small peak at about 12 min. The
major peak was presumptively identiﬁed as polyglycol mono- and
di-esters (lipophilic portion) and the small peak as the free PEG.
The GPC method did not disclose the details for quantitative es-
timation of kolliphor HS15, because the method focused on the
reversal of multidrug resistance for various fractions of kolliphor
HS15. Bhaskar et al. [13] developed a liquid chromatography/tan-
dem mass spectrometry (LC–MS/MS) method for the determina-
tion of kolliphor HS15. The LC–MS/MS method was operated with
a C18 column and 5 min generic gradient. Mobile phase A was 0.1%
formic acid in water and mobile phase B was 100% acetone. This
study found that the most abundant ions corresponding to kolli-
phor HS15 were free PEG oligomers (hydrophilic portion). Per-
centages of the lipophilic and hydrophilic components in kolliphor
HS15 were estimated using a high performance liquid chromato-
graphy (HPLC) system equipped with an evaporative light scat-
tering detector (ELSD). The method required a time-consuming
protein extraction prior to analysis.
In our present work, kolliphor HS15 and miglyol 812 were both
formulated into microemulsion products as the stabilizer and
emulsifying agent. The aim of this study was to develop and va-
lidate an analytical method for simultaneous determination of
kolliphor HS15 and miglyol 812 in a single run.2. Experimental
2.1. Materials and reagents
Kolliphor HS15 raw material was purchased from BASF Com-
pany (Iselin, New Jersey, USA) and miglyol 812 raw material was
provided by Sasol Germany GmbH (Eatontown, New Jersey, USA).
Polyoxyl 15 hydroxystearate reference standard was purchased
from U.S. Pharmacopeia Co. (Rockville, Maryland, USA). Caprylic
acid triglyceride, capric acid triglyceride and polyethylene glycol
were all purchased from Sigma-Aldrich Co. (St. Louis, Missouri,
USA). HPLC-grade acetonitrile, 0.1% triﬂuoroacetic acid (TFA) in
water and isopropanol (IPA) were purchased from Thermos Fisher
Scientiﬁc (Fair Lawn, New Jersey, USA). Water was puriﬁed by aMillipore–Q academic water puriﬁcation system (Billerica, Mas-
sachusetts, USA). All other chemicals and reagents used for the
experiments were of analytical grade.
2.2. Instruments
An Acquity™ ultra-high performance liquid chromatography
(UHPLC™) system (Waters, Milford, Massachusetts, USA) coupled
with a nano quantity analyte detector (NQAD™, Quant, Blaine,
Minnesota, USA) was used for simultaneous determination of
kolliphor HS15 and miglyol 812. The UHPLC system consisted of a
binary solvent manager, a sample manager and a column manager.
System control and data analysis were processed with Empower II
software (Waters, Milford, Massachusetts, USA). The NQAD in-
strument consisted of a 500 mL water bottle, a liquid nebulizer, a
solvent evaporator, a patented water condensation particle coun-
ter (WCPC) and an optical detector. Three ethylene bridged hybrid
(BEH) UHPLC columns including BEH C18, BEH Shield RP18, BEH
phenyl and one high strength silica (HSS) T3 column (Waters,
Milford, Massachusetts, USA) were selected for column screening.
The mobile phases consisted of 0.1% TFA in water as the aqueous
component (A) and 100% acetonitrile as the organic modiﬁer (B). A
gradient elution sequence was programed initially with 60% or-
ganic solvent, slowly increased to 100% within 8 min and held for
5 min. The ﬂow rate was set at 0.7 mL/min and the injection vo-
lume was 10 mL. The column temperature was maintained at 30 °C
and the autosampler temperature was kept at ambient tempera-
ture (about 25 °C). The NQAD was operated with default settings
as follows: nitrogen (N2) gas: 28.0 psi, nebulization temperature:
40 °C, and evaporation temperature: 60 °C.
2.3. Preparation of solutions
2.3.1. Standard solutions
A combination of IPA/water (65:35, v/v) was used as the diluent
for kolliphor HS15 and miglyol 812. Polyoxyl 15 hydroxystearate
reference standard stock solution was prepared in diluent at a
concentration of approximately 25 mg/mL. The working standard
solution was prepared by pipetting 2 mL of standard stock solution
into a 50 mL volumetric ﬂask and diluted to volume with diluent
at a concentration of approximately 1000 mg/mL. Caprylic acid
triglyceride and capric acid triglyceride reference standard
stock solutions were prepared in diluent at a concentration of
approximately 4 mg/mL each. The working standard solutions of
caprylic acid triglyceride and capric acid triglyceride were pre-
pared, respectively, by pipetting 2 mL of each of standard stock
solution into 50 mL volumetric ﬂasks and diluted to volume with
diluent at a concentration of approximately 160 mg/mL. The above
standard stock and working solutions were stored at 4 °C until use.
2.3.2. Microemulsion placebo sample
The microemulsion placebo sample was prepared by weighing
each of the components, excluding kolliphor HS15 and miglyol
812, into a 100 mL glass volumetric ﬂask and diluted to volume
with diluent. This microemulsion placebo sample was used for
accuracy sample spiking.
2.3.3. System suitability samples
System suitability samples were daily prepared by pipetting
2 mL of each of polyoxyl 15 hydroxystearate, caprylic acid trigly-
ceride and capric acid triglyceride stock solutions into a 50 mL
volumetric ﬂask, mixed well and diluted to volume with diluent.
2.3.4. Linearity and accuracy samples
Five levels (quantitation limit (QL), 25%, 50%, 100% and 125%) of
the linearity samples were prepared by serial dilutions of standard
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125% of each component assay level. Three levels (50%, 100% and
125%) of the accuracy samples were prepared in triplicate by
pipetting 1.0, 2.0 and 2.5 mL of each of the standard stock solu-
tions into 50 mL volumetric ﬂasks containing 1.0 mL of micro-
emulsion placebo solution, respectively, and diluted to volume
with diluent.
2.3.5. Microemulsion assay sample
Microemulsion assay samples were prepared by weighing
(50075.0) mg of microemulsion formulation into a 50 mL volu-
metric ﬂask and diluted to volume with diluent. Each assay sample
contained approximately 1000 mg/mL of kolliphor HS15 and
300 mg/mL of miglyol 812.3. Results and discussion
3.1. Method development
Our method development strategy was implemented following
Quality-by-Design (QbD) principles including diluent selection,
mobile phase selection, column screening, column temperature
determination and instrumental parameter determination. Meth-
od development samples were prepared using each of individual
reference standard of polyoxyl 15 hydroxystearate, caprylic acid
triglyceride and capric acid triglyceride.
3.1.1. Diluent selection
The development of this method started with the selection of a
diluent that was suitable not only for dissolving kolliphor HS 15
and miglyol 812, but also for being compatible with the mobile
phase. If the diluent is stronger than the mobile phase, it will drag
the compound through the column, resulting in peak splitting or
broadening. Kolliphor HS 15 is soluble in polar solvents such as
water, ethanol and isopropanol to form clear solutions, while
miglyol 812 is soluble in medium polar solvents such as diethyl
ether and ethyl acetate. Therefore, the diluent for kolliphor HS15
and miglyol 812 should be a mixture of polar and medium polar
solvents.
Diluent selection study was performed on three combinations,
i.e., water/methanol, water/IPA and water/acetonitrile. It was
concluded that 65% IPA in water produced clear stock solutions for
polyoxyl 15 hydroxystearate, caprylic acid triglyceride and capric
acid triglyceride. The similar clear stock solutions for polyoxyl 15
hydroxystearate, caprylic acid triglyceride and capric acid trigly-
ceride were obtained with a combination of 75% methanol in
water or a combination of 85% acetonitrile in water. Chromato-
grams of the sample prepared using 65% IPA in water showed
three sharp peaks. Chromatograms of the samples prepared using
75% methanol in water or 85% acetonitrile in water gave polyoxyl
15 hydroxystearate a wide broad peak. Therefore, a combination of
65% IPA in water was selected as the diluent.
3.1.2. Mobile phase selection
Proper combination of water and organic solvents with differ-
ent polarities is very important for achieving ideal chromato-
graphic separations. Knowing the polarities of kolliphor HS15 and
miglyol 812, this method development started with an elution
program with an aqueous, moderately polar mobile phase for
kolliphor HS15 that was weakly adsorbed to the stationary phase
ﬁrst. The polarity of mobile phase was then decreased by in-
creasing the percentage of organic solvent for miglyol 812. In this
study, three sets of mobile phase combinations including water/
methanol, 0.1% TFA in water/methanol, and 0.1% TFA in water/
acetonitrile were evaluated. A gradient elution sequence wasprogramed initially with 60% organic solvent, slowly increased to
100% within 8 min, and held constantly for 5 min to make a total
run time of 13 min. This study found that a combination of water/
methanol under optimized elution program gave kolliphor
HS15 (polyoxyl 15 hydroxystearate) a broad peak and could not
separate caprylic acid triglyceride and capric acid triglyceride due
to the mismatch polarity of mobile phase with these two fatty acid
triglycerides. A combination of 0.1% TFA in water/methanol
showed the similar chromatogram as water/methanol mobile
phase, because the organic solvent programmed in most of elution
time was methanol. It implied that the polarity of kolliphor HS15
was less than the polarity of the combination of water or 0.1% TFA
in water and methanol, yielding a broad and tailing peak for kol-
liphor HS15. The third combination (0.1% TFA in water/acetonitrile)
was evaluated. It gave a very nice peak shape for polyoxyl 15 hy-
droxystearate and well separated caprylic acid triglyceride and
capric acid triglyceride peaks. Therefore, a combination of 0.1% TFA
in water/acetonitrile was selected as the mobile phase for further
study.
3.1.3. Column screening
Column selection for chromatographic analysis was also an
important step in method development. This study utilized a
chromatographic basic rule “like attracts like” and focused on the
polarity matching among column stationary phase, mobile phase,
kolliphor HS15 and miglyol 812. Kolliphor HS15 is a relatively
polar compound and soluble in water. Miglyol 812 is a medium
polar compound and soluble in isopropanol. When an aqueous,
moderately polar mobile phase was used, the column stationary
phase should be a non-polar material for relatively polar or
medium polar components in kolliphor HS15 and miglyol 812.
In this study, three UHPLC BEH columns (namely BEH C18, BEH
Shield RP18, BEH phenyl) and one HSS T3 column were evaluated
for column screening. The columns used in the study were all
2.1 mm  100 mm i.d., 1.7 μm particle size, with the exception of
the HSS T3 column, which has 1.8 μm particle size. The column
temperature was kept at 30 °C. The chromatographic parameters
were ﬁrst optimized to achieve good retention, high resolution
and better peak shapes for the components in kolliphor HS15 and
miglyol 812.
Because of its good robustness and stability, the BEH C18 was
selected as the prime column for the screening. The BEH C18 in-
corporated trifunctional ligand bonding chemistries and utilized
new, proprietary endcapping processes for good peak shapes. The
BEH C18 was designed for the analysis of polar or medium polar
compounds [14]. In the experiment, the BEH C18 eluted three sharp
peaks with minimal peak tailing for polyoxyl 15 hydroxystearate at
a retention time of about 2.1 min, caprylic acid triglyceride at
about 7.6 min, and capric acid triglyceride at about 9.8 min. The
BEH C18 column also afforded a good resolution between caprylic
acid triglyceride and capric acid triglyceride. It demonstrated that
the BEH C18 column chemistry closely matched the polarity of
kolliphor HS 15 and miglyol 812. The chromatogram obtained
from the BEH C18 column screening preliminarly concluded that
this column was appropriate and met the method requirement.
However, additional column screening was continued for the
purposes of developing more useful methods for future trouble
shooting.
The second column evaluated was the HSS T3. The column
chemistries of HSS T3 and BEH C18 are similar. The HSS T3 column
contained 100% silica particles and utilized T3 bonding process to
retain and separate polar compounds. The HSS T3 column was
designed for separation of polar compounds because of its su-
perior polar-compound retention and aqueous mobile phase
compatibility. In this study, the HSS T3 column could separate
kolliphor HS15, caprylic acid triglyceride and capric acid
Fig. 1. Microemulsion placebo solution chromatogram.
Fig. 2. System suitability chromatogram.
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time of polyoxyl 15 hydroxystearate was delayed about 0.5 min
and the peak area was decreased by 25%, possibly due to the dif-
ference of particle sizes. It implied that the HSS T3 column might
attract traces of components in its stationary phase.
The third column studied was the BEH Shield RP18 column. The
stationary phase of BEH Shield RP18 column combined the hy-
drophobicity alkyl ligand and the hydrophilicity polar group. It is
dedicated for complement of BEH C18 and BEH C8 phases. In the
experiment, the BEH Shield RP18 column could not separate the
peaks of caprylic acid triglyceride and capric acid triglyceride,
proving that the polarity of BEH Shield RP18 was not matched to
that of medium chain fatty acid triglyceride components.
The BEH phenyl column was the fourth column screening,
which contained phenyl ligand and utilized a trifunctional C6 alkyl
ether between the phenyl ring and the silyl functionality, which
was dedicated for the analysis of polymer additives. In this study,
the BEH phenyl column could well separate polyoxyl 15 hydro-
xystearate, caprylic acid triglyceride and capric acid triglyceride
with better peak shapes, but the resolution between caprylic acid
triglyceride and capric acid triglyceride reduced when compared
with the BEH C18. It implied that this column was not suitable for
miglyol 812, because this resolution (o1.1) would not have spaces
for the two by-products components between caprylic acid tri-
glyceride and capric acid triglyceride.
Based on the above optimized methods for column screening,
the results proved that the BEH C18 column afforded the best re-
tention and separation of all components in kolliphor HS15 and
miglyol 812. Hence, the BEH C18 column was selected for further
study.
3.1.4. Column temperature determination
Three column temperatures were evaluated during method
development, namely, ambient temperature (approximately
20 °C), 30 °C and 45 °C. Determination was carried out based on a
visual check of chromatogram and a comparison of peak areas. The
ambient column temperature (approximately 20 °C) often in-
creased the UHPLC system back pressure (415,000 psi) because
the lower column temperature increased the mobile phase visc-
osity. Furthermore, higher mobile phase viscosity also reduced the
diffusion in the chromatographic system, giving broad peaks. In
general, higher temperature has proven effective for improving
the overall chromatographic performance, but the column tem-
perature of 45 °C eluted components faster and decreased the
resolution of four component peaks in miglyol 812, resulting in a
poor separation of miglyol 812. Interestingly, a comparison of
three major peak areas in kolliphor HS15 and miglyol 812 showed
that the differences were less than 3.1% when using 30 °C and
45 °C for column separation. Hence, the column temperature of
30 °C was determined for further study.
3.1.5. Nano quantitation analyte detector (NQAD)
Kolliphor HS15 and miglyol 812 contain very weak ultraviolet
(UV) absorbance and cannot be analyzed using UV detection. The
NQAD detector is a new aerosol-based detector and incorporates
four chambers: nebulization, evaporation, aerosol particle counter
and an optical detection. The NQAD detector begins by con-
tinuously nebulizing the liquids eluted from the LC column into
various sizes of droplet mists containing solvents and sample
particles. In the evaporation chamber, the solvents are evaporated
by nitrogen ﬂow and the sample particles are suspended in air. In
the third chamber, a WCPC condenses the water vapor onto the
particle surfaces to enlarge them to a size large enough for
counting. In the end, the number of sample particles is detected
individually by an optical detector and converted to an analog
output signal as a chromatogram. Unlike other aerosol-baseddetectors that measure a cloud of particles, the NQAD detector
counts each individual droplet [15]. It is minimally affected by
baseline drift and maximally increases the method sensitivity. In
this study, the temperatures of nebulization and evaporation
chambers were evaluated. We found that a slight change in tem-
peratures of the nebulization and evaporation would not sig-
niﬁcantly impact the method detection. The NQAD detector was
then operated with typical settings as follows: nitrogen (N2) gas:
28.0 psi, nebulization temperature: 40 °C, and evaporation tem-
perature: 60 °C.
3.2. Method validation
The proposed method was validated for speciﬁcity, linearity,
accuracy, precision, sensitivity and robustness as per ICH method
validation guidelines [16].
3.2.1. Speciﬁcity
Microemulsion placebo solution was injected each time prior to
study and checked for the potential interference of peaks at the
retention times of polyoxyl 15 hydroxystearate, caprylic acid tri-
glyceride and capric acid triglyceride.
A typical microemulsion placebo solution chromatogram is
shown in Fig. 1 and no interfering peaks were found at the re-
tention times of kolliphor HS 15 and miglyol 812.
3.2.2. System suitability
System suitability test is an integral part of the method vali-
dation and used to conﬁrm that the resolution, peak tailing and
reproducibility were adequate for the analysis performed.
A typical system suitability chromatogram is shown in Fig. 2. It
shows that all three major components were well separated with
symmetric peak shapes. Two unidentiﬁed peaks were conﬁrmed
to be free PEG from polyoxyl 15 hydroxystearate by co-injection of
free PEG reference standard. The detailed results of system suit-
ability samples are shown in Table 1.
Table 1 shows that the average relative standard deviation (RSD,
n¼6) of peak areas was 0.7% for polyoxyl 15 hydroxystearate, 0.4%
for caprylic acid triglyceride, and 0.6% for capric acid triglyceride.
The resolution of polyoxyl 15 hydroxystearate/caprylic acid
Table 1
Results of system suitability samples.
Components Retention time
(min)
Resolution Tailing
factor
RSD (%)
(n¼6)
Polyoxyl 15
hydroxystearate
2.75 – 1.13 0.7
Caprylic acid triglyceride 8.50 10.4 1.35 0.4
Capric acid triglyceride 11.81 16.6 1.09 0.6
Table 4
The intra-day and inter-day precision results.
Components Precision (RSD%) Difference (%)
Intra-day Inter-day
Polyoxyl 15 hydroxystearate 1.7 0.4 0.3
Caprylic acid triglyceride 1.6 2.7 1.7
Capric acid triglyceride 0.6 0.4 4.3
Table 5
Results of detection limit (DL) and quantiﬁcation limit (QL).
Components DL (mg/mL) QL (mg/mL)
Polyoxyl 15 hydroxystearate 5.5 27.6
Caprylic acid triglyceride 0.4 0.8
Capric acid triglyceride 0.9 2.7
H. Zhang et al. / Journal of Pharmaceutical Analysis 6 (2016) 11–17 15triglyceride peaks was 10.4 and the resolution of caprylic acid tri-
glyceride/capric acid triglyceride peaks was 16.6. The tailing factors
of the three component peaks were less than 2.0.
3.2.3. Linearity
Linearity samples were serially diluted from each individual
standard stock solution to obtain ﬁve concentration levels, cover-
ing QL to 125% of the assay level. The peak areas at each level of
polyoxyl 15 hydroxystearate, caprylic acid triglyceride and capric
acid triglyceride were calculated to assess the method linearity.
Calibration curves were constructed for each individual standard
by plotting the concentration of each individual standard versus
peak area responses. The regression equations were calculated
from the calibration graphs, along with the standard deviations of
the slope and intercept on the ordinate. The detailed results are
shown in Table 2.
3.2.4. Accuracy/recovery
Analytical recovery experiments were performed by adding
known amount of polyoxyl 15 hydroxystearate, caprylic acid tri-
glyceride and capric acid triglyceride standard stock solutions into
a 50 mL ﬂask each containing 1.0 mL of microemulsion placebo
solution. The average recoveries of three levels (50%, 100% and
125%) were 100.4%, 98.0% and 100.0%, respectively, for polyoxyl 15
hydroxystearate, caprylic acid triglyceride and capric acid trigly-
ceride. The results demonstrated that the method has sufﬁcient
capability for the accurate quantiﬁcation of kolliphor HS15 and
miglyol 812 samples. Detailed accuracy/recovery results are given
in Table 3.Table 2
Linearity sample concentrations and results.
Components Concentration (mg/mL)
QL 25% 50% 100%
Polyoxyl 15 hydroxystearate 27.6 276.2 552.4 1104.8
Caprylic acid triglyceride 0.8 40.4 121.2 161.8
Capric acid triglyceride 2.7 44.4 88.7 177.5
Table 3
The accuracy results of samples.
Components Level (%) Conc. added
(mg/mL)
Average conc. found
(mg/mL) (n¼3)
Polyoxyl 15 hydroxystearate 50 552.4 552.5
100 1104.8 1120.5
125 1381.0 1376.4
Caprylic acid triglyceride 50 80.8 78.1
100 161.6 157.7
125 202.0 201.2
Capric acid triglyceride 50 88.7 83.5
100 177.5 183.4
125 221.9 227.53.2.5. Precision
Intra- and inter-day precisions were evaluated. The intra-day
precision was evaluated using the results of six preparations each
containing three components, polyoxyl 15 hydroxystearate,
caprylic acid triglyceride and capric acid triglyceride. The inter-day
precision was evaluated by analyzing the same sample in duplicate
for two days. Detailed intra-day and inter-day precision results are
given in Table 4.
The intra-day RSD values of all three components were lower
than 2.0% and the inter-day RSD values of all three components
were lower than 3.0%. The differences of the mean from two days
were 0.3%, 1.7% and 4.3%, respectively, for polyoxyl 15 hydro-
xystearate, caprylic acid triglyceride and capric acid triglyceride.
3.2.6. Detection limit (DL) and QL
Method sensitivity was assessed at DL and QL. The DL and QL of
kolliphor HS15 and miglyol 812 were determined by injecting pro-
gressively low concentration of the reference standard solution under
the chromatographic conditions (Table 5). The lowest concentration
assayed was regarded as QL where the signal-to-noise ratio was at
least 10:1. The DL was deﬁned as a signal-to-noise ratio of 3:1.Regression equations (Y¼axþb) Correlation coefﬁcient (r)
125%
1381.1 Y¼901.8 xþ8736.9 0.9980
202.0 Y¼2590.7xþ 25,819 0.9920
221.9 Y¼1179.0x þ3352 0.9825
Average recovery (%)
(n¼3)
Overall average recovery (%)
(n¼9)
RSD (%) (n¼9)
100.0 100.4 1.5
101.4
99.7
96.7 98.0 2.0
97.6
99.6
94.1 100.0 5.8
103.3
102.5
Fig. 3. Chromatogram of kolliphor HS15 raw material.
Fig. 4. Chromatogram of miglyol 812 raw material.
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Robustness was evaluated by deliberating variations in UHPLC–
NQAD method parameters, one at a time. In this study, four ex-
perimental conditions were slightly varied, including ﬂow rate,
column temperature, nebulizer temperature and evaporation
temperature. Robustness results are summarized in Table 6.
Robustness results demonstrated that a little variation of
method parameters would not signiﬁcantly change the test results,
except for the result of caprylic acid triglyceride under ﬂow rate
change. When the ﬂow rate was varied from 0.7 to 0.6 mL/min, the
peak area of caprylic acid triglyceride was reduced about 12.41%.
As a result, its retention time was delayed about 0.5 min and the
peak was completely detached from the bottom of free PEG
2 peak.
3.3. Method applications
The analytical method was successfully developed and has
been applied in analyses of kolliphor HS15, miglyol 812 and mi-
croemulsion formulation samples.
3.3.1. Analysis of kolliphor HS15 raw material
Due to the difﬁculty of lipophilic analysis, current available
methods for kolliphor HS15 are applicable only to the analysis of
non-esteriﬁed hydrophilic components, such as USP–NF and Ph.
Eur. Methods [11,12].
This UHPLC–NQAD method has a capability of direct de-
termination of both lipophilic and hydrophilic parts without
sample derivatization. A short gradient sequence was programed
and gave a good separation between lipophilic and hydrophilic
parts (Fig. 3).
Three free PEG components were identiﬁed and conﬁrmed
by co-injection of free PEG reference standard solution. Content
(%) of each component was estimated by area normalization
method, where the percentage of each component was divided
by summing up peak areas of all the components to 100%. Re-
tention time of lipophilic component peak was about 2.1 min
and three free PEG components peaks were about 6.0, 7.1 and
8.6 min. Content (%) of lipophilic component was found to be
67.8%, and three free PEG components were 14.7%, 10.7% and
6.9%. The content (%) of total free PEG components was 32.3%
and in match with USP–NF acceptance criteria of 27.0% to 39.0%
for free PEG.
3.3.2. Analysis of miglyol 812 raw material
Miglyol 812 raw material is a mixture of caprylic triglyceride/
capric acid triglyceride obtained by the esteriﬁcation of caprylicTable 6
Robustness test results.
Parameters Polyoxyl 15 hydroxystearate Caprylic
Peak area Diff. (%) Peak are
Flow rate (mL/min)
0.7 1,459,980 611,306
0.6 1,499,094 2.68 535,450
Column temperature (°C)
30 1,183,531 557,103
45 1,174,089 0.80 554,693
Evaporation temperature
in NQAD (°C)
45 1,313,528 451,385
60 1,307,247 0.48 449,095
Nebulization temperature
in NQAD (°C)
35 1,307,247 449,895
40 1,295,625 0.89 463,539acid and capric acid with glycerin. The ratio of caprylic acid and
capric acid participated in esteriﬁcation with glycerin is about
60:40(v/v). The resulted triglyceride mixture contained four
components, caprylic triglyceride (C8–C8–C8), by-product A
(C8–C8–C10), by-product B (C8–C10–C10) and capric triglyceride
(C10–C10–C10). Caprylic triglyceride/capric acid triglyceride contain
very weak UV absorbance and cannot be directly detected using
UV. In this UHPLC–NQAD method, a short gradient elution gave a
good separation for all four component peaks (Fig. 4).
Components of caprylic triglyceride and capric triglyceride in
miglyol 812 raw material were identiﬁed and conﬁrmed by in-
dividually co-injecting caprylic triglyceride and capric triglyceride
reference standard solution. Contents (%) of four triglyceride peaks
were estimated by area normalization method, where the per-
centage of each triglyceride was divided by summing up peak area
of all the triglycerides to 100%. The retention time of four trigly-
ceride peaks was about 7.6, 8.3, 9.0 and 9.8 min and their contents
(%) were 39.9%, 43.5%, 12.8%, and 3.8%, respectively.
3.3.3. Analysis of microemulsion formulation
A sample of microemulsion product formulated with Kolliphor
HS15 and miglyol 812 was analyzed using this UHPLC–NQAD
method and the chromatogram was obtained as shown in Fig. 5. Itacid triglyceride Capric acid triglyceride
a Diff. (%) Peak area Diff. (%)
607,004
12.41 617,440 1.72
498,911
0.43 483,495 3.09
456,791
0.51 464,495 1.69
463,749
3.03 474,011 2.21
Table 7
Recoveries of all components in kolliphor HS15.
Components Kolliphor HS15 raw
material (%)
Microemulsion formula-
tion (%)
Recovery (%)
Lipophilic 67.7 69.6 102.8
Free PEG 1 14.7 15.2 103.4
Free PEG 2 10.7 8.8 82.2
Free PEG 3 6.9 6.4 92.8
Total free PEG 32.3 30.4 94.1
Table 8
Recoveries of all components in miglyol 812.
Components Miglyol 812 raw
material (%)
Microemulsion formula-
tion (%)
Recovery (%)
C8-triglyceride 39.9 41.1 103.0
By-product A 43.5 43.2 99.3
By-product B 14.4 13.8 95.8
C10-triglyceride 2.1 2.0 95.2
Fig. 5. Chromatogram of microemulsion formulation.
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HS15 and two by-products in miglyol 812 were well separated.
The content (%) of each component is given in Tables 7 and 8.
Recovery (%) of each component in microemulsion formulation
was calculated using the same component found in kolliphor HS15
and miglyol 812 raw materials.
Recoveries (%) of four components in kolliphor HS15 were
82.2%–103.4% and recoveries of four components in miglyol 812
was 95.2%–103.0%. The results indicated that no component in
kolliphor HS15 and miglyol 812 was signiﬁcantly lost during the
formulation of microemulsion product. Furthermore, it proved this
method was reliable, accurate and effective for simultaneous
quantiﬁcation of kolliphor HS15 and miglyol 812 in microemulsion
formulation.4. Conclusion
A rapid, sensitive and robust UHPLC–NQAD method has been
developed and validated for simultaneous determination ofkolliphor HS15 and miglyol 812 in microemulsion formulation. All
components were well separated using Acquity BEH C18 column
with a short gradient elution chromatography. Good selectivity
and sensitivity were achieved by this UHPLC–NQAD method. The
validated method has been successfully applied to assay of mi-
croemulsion formulation sample and the results proved that
method is acceptable and reliable.Acknowledgments
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